Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials
- PMID: 20044651
- DOI: 10.1192/bjp.bp.108.062984
Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials
Abstract
Background: Many patients with borderline personality disorder receive pharmacological treatment, but there is uncertainty about the usefulness of such therapies.
Aims: To evaluate the evidence of effectiveness of pharmacotherapy in treating different facets of the psychopathology of borderline personality disorder.
Method: A Cochrane Collaboration systematic review and meta-analysis of randomised comparisons of drug v. placebo, drug v. drug, or single drug v. combined drug treatment in adult patients with borderline personality disorder was conducted. Primary outcomes were overall disorder severity as well as specific core symptoms. Secondary outcomes comprised associated psychiatric pathology and drug tolerability.
Results: Twenty-seven trials were included in which first- and second-generation antipsychotics, mood stabilisers, antidepressants and omega-3 fatty acids were tested. Most beneficial effects were found for the mood stabilisers topiramate, lamotrigine and valproate semisodium, and the second-generation antipsychotics aripiprazole and olanzapine. However, the robustness of findings is low, since they are based mostly on single, small studies. Selective serotonin reuptake inhibitors so far lack high-level evidence of effectiveness.
Conclusions: The current evidence from randomised controlled trials suggests that drug treatment, especially with mood stabilisers and second-generation antipsychotics, may be effective for treating a number of core symptoms and associated psychopathology, but the evidence does not currently support effectiveness for overall severity of borderline personality disorder. Pharmacotherapy should therefore be targeted at specific symptoms.
Comment in
-
Antipsychotics and borderline personality disorder.Br J Psychiatry. 2010 Apr;196(4):332; author reply 332. doi: 10.1192/bjp.196.4.332. Br J Psychiatry. 2010. PMID: 20357314 No abstract available.
Similar articles
-
Pharmacological interventions for borderline personality disorder.Cochrane Database Syst Rev. 2010 Jun 16;(6):CD005653. doi: 10.1002/14651858.CD005653.pub2. Cochrane Database Syst Rev. 2010. PMID: 20556762 Free PMC article. Review.
-
Evidenced-based pharmacologic treatment of borderline personality disorder: a shift from SSRIs to anticonvulsants and atypical antipsychotics?J Affect Disord. 2008 Nov;111(1):21-30. doi: 10.1016/j.jad.2008.01.024. Epub 2008 Mar 4. J Affect Disord. 2008. PMID: 18304647 Review.
-
Pharmacotherapy for borderline personality disorder--current evidence and recent trends.Curr Psychiatry Rep. 2015 Jan;17(1):534. doi: 10.1007/s11920-014-0534-0. Curr Psychiatry Rep. 2015. PMID: 25413640 Review.
-
Efficacy and tolerability of pharmacotherapies for borderline personality disorder.CNS Drugs. 2008;22(8):671-92. doi: 10.2165/00023210-200822080-00005. CNS Drugs. 2008. PMID: 18601305 Review.
-
Pharmacotherapy of borderline personality disorder: a systematic review for publication purpose.Curr Med Chem. 2011;18(22):3322-9. doi: 10.2174/092986711796504682. Curr Med Chem. 2011. PMID: 21728970 Review.
Cited by
-
Prescription of topiramate to treat alcohol use disorders in the Veterans Health Administration.Addict Sci Clin Pract. 2013 Jul 8;8(1):12. doi: 10.1186/1940-0640-8-12. Addict Sci Clin Pract. 2013. PMID: 23835352 Free PMC article.
-
Pharmacological interventions for borderline personality disorder.Cochrane Database Syst Rev. 2010 Jun 16;(6):CD005653. doi: 10.1002/14651858.CD005653.pub2. Cochrane Database Syst Rev. 2010. PMID: 20556762 Free PMC article. Review.
-
A Bayesian Account of Psychopathy: A Model of Lacks Remorse and Self-Aggrandizing.Comput Psychiatr. 2018 Oct;2:92-140. doi: 10.1162/cpsy_a_00016. Comput Psychiatr. 2018. PMID: 30381799 Free PMC article.
-
Efficacy and Safety of Aripiprazole in Borderline Personality Disorder: A Systematic Review.Psychiatr Q. 2023 Dec;94(4):541-557. doi: 10.1007/s11126-023-10045-8. Epub 2023 Aug 11. Psychiatr Q. 2023. PMID: 37566261 Review.
-
Standard set of patient-reported outcomes for personality disorder.Qual Life Res. 2021 Dec;30(12):3485-3500. doi: 10.1007/s11136-021-02870-w. Epub 2021 Jun 2. Qual Life Res. 2021. PMID: 34075531 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources